Top

Molecular Cancer

Published in:

Open Access 01-12-2009 | Research

Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients

Author: Samy L Habib

Published in: Molecular Cancer | Issue 1/2009

Abstract

Background

The tuberous sclerosis complex (TSC) is caused by defects in one of two tumor suppressor genes, TSC-1 or TSC-2. TSC-2 gene encodes tuberin, a protein involved in the pathogenesis of kidney tumors, both angiomyolipomas and renal cell carcinomas. Loss of heterozygosity at the 8-oxoG-DNA glycosylase (OGG1) allele is found in human kidney clear cell carcinoma identifying loss of OGG1 function as a possible contributor to tumorigenesis in the kidney. Tuberin regulates OGG1 through the transcription factor NF-YA in cultured cells. The purpose of this study is to determine the effect of tuberin-deficiency on OGG1 protein and mRNA levels as well as on 8-oxodG levels in kidney tumors from patients with TSC. In addition we evaluated the phophorylation level of downstream targets of mTOR, phospho-S70K, in kidney tumor tissue from TSC patients.

Results

Kidney angiomyolipoma tissue from TSC patients expresses significant levels of phopho-tuberin and low levels of tuberin compared to control kidney tissue. The increase in tuberin phosphorylation and the decrease tuberin expression are associated with decrease in OGG1 protein and mRNA levels in tumor samples compared to normal kidney samples. The decrease OGG1 expression is also associated with significant decrease in the transcription factor, NF-YA, expression in tumor samples compared to normal tissues. In addition, the levels of 8-oxodG are 4-fold higher in tumors compared to control samples. The significant increase of phospho-tuberin expression is associated with increase phosphorylation of S6K in tumor samples compared to controls. Cyclin D1 expression is also 3-fold higher in increase in the tumor tissues compared to normal kidney tissues.

Conclusion

These data indicate that tuberin deficiency in angiomyolipoma enhances mTOR activation by phosphorylation of S6K and downregulation of protein and mRNA expression of OGG1 resulted in accumulation of oxidized DNA in patients with TSC. These data suggest that tuberin and OGG1 are important proteins in the pathogenesis of angiomyolipoma in TSC patients.

Available only for authorised users

Osborne JP, Fryer A, Webb D: Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991, 615: 125-127. 10.1111/j.1749-6632.1991.tb37754.xCrossRefPubMed

Stillwell TJ, Gomez MR, Kelalis PP: Renal lesions in tuberous sclerosis. J Urol. 1987, 138: 477-481.PubMed

Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, Fujikawa K, Bjornsson J, Bernstein J, Henske EP: Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998, 83: 2208-2216. 10.1002/(SICI)1097-0142(19981115)83:10<2208::AID-CNCR21>3.0.CO;2-KCrossRefPubMed

Parry L, Maynard JH, Patel A, Clifford SC, Morrissey C, Maher ER, Cheadle JP, Sampson JR: Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer. 2001, 85: 1226-1230. 10.1054/bjoc.2001.2072PubMedCentralCrossRefPubMed

Shapiro RA, Skinner DG, Stanley P, Edelbrock HH: Renal tumors associated with tuberous sclerosis: the case for aggressive surgical management. J Urol. 1984, 132: 1170-1174.PubMed

Astrinidis A, Henske EP: Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005, 24: 7475-7481. 10.1038/sj.onc.1209090CrossRefPubMed

Jozwiak J: Hamartin and tuberin working together for tumour suppression. Int J Cancer. 2006, 118: 1-5. 10.1002/ijc.21542CrossRefPubMed

Li Y, Inoki K, Guan KL: Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol. 2004, 24: 7965-7975. 10.1128/MCB.24.18.7965-7975.2004PubMedCentralCrossRefPubMed

Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002, 10: 151-62. 10.1016/S1097-2765(02)00568-3CrossRefPubMed

10.

Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem. 2002, 277: 35364-35370. 10.1074/jbc.M205838200CrossRefPubMed

11.

Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002, 4: 648-657. 10.1038/ncb839CrossRefPubMed

12.

Nishigori C, Hattori Y, Toyokuni S: Role of reactive oxygen species in skin carcinogenesis. Antioxid Redox Signal. 2004, 3: 561-70. 10.1089/152308604773934314.CrossRef

13.

Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, Dogliotti E: 8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways. Mutat Res. 2003, 531: 127-139.CrossRefPubMed

14.

Boiteux S, Radicella JP: The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys. 2000, 377: 1-8. 10.1006/abbi.2000.1773CrossRefPubMed

15.

Dhenaut A, Boiteux S, Radicella JP: Characterization of the hOGG1 promoter and its expression during the cell cycle. Mutat Res. 2000, 461: 109-118.CrossRefPubMed

16.

Guibourt N, Boiteux S: Expression of the Fpg protein of Escherichia coli in Saccharomyces cerevisiae: effects on spontaneous mutagenesis and sensitivity to oxidative DNA damage. Biochimie. 2000, 82: 59-64. 10.1016/S0300-9084(00)00357-6CrossRefPubMed

17.

Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, Seeberg E, Lindahl T, Barnes DE: Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci USA. 1999, 96: 13300-5. 10.1073/pnas.96.23.13300PubMedCentralCrossRefPubMed

18.

Chevillard S, Radicella JP, Levalois C, Lebeau J, poupon MF, Oudard S, Dutrillaux B, Boiteux S: Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours. Oncogene. 1998, 16: 3083-3086. 10.1038/sj.onc.1202096CrossRefPubMed

19.

Audebert M, Chevillard S, Levalois C, Gyapay G, Vieillefond A, Klijanienko J, Vielh P, El Naggar AK, Oudard S, Boiteux S, Radicella JP: Alterations of the DNA repair gene OGG1 in human clear cell carcinomas of the kidney. Cancer Res. 2000, 60: 4740-4744.PubMed

20.

Lee MR, Kim SH, Cho HJ, Lee KY, Moon AR, Jeong HG, Lee JS, Hyun JW, Chung MH, You HJ: Transcription factors NF-YA regulate the induction of human OGG1 following DNA-alkylating agent methylmethane sulfonate (MMS) treatment. J Biol Chem. 2004, 279: 9857-9866. 10.1074/jbc.M311132200CrossRefPubMed

21.

Habib SL, Phan MN, Patel SK, Li D, Monks TJ, Lau SS: Reduced constitutive 8-oxoguanine-DNA glycosylase expression and impaired induction following oxidative DNA damage in the tuberin deficient Eker rat. Carcinogenesis. 2003, 24: 573-582. 10.1093/carcin/24.3.573CrossRefPubMed

22.

Habib SL, Simone S, Barnes JJ, Abboud HE: Tuberin Haploinsufficiency is Associated with the Loss of OGG1 in Rat Kidney Tumors. Molecular Cancer. 2008, 7: 10-14. 10.1186/1476-4598-7-10PubMedCentralCrossRefPubMed

23.

Habib SL, Riley DJ, Bhandari B, Mahimainathan L, Choudhury GG, Abboud HE: Tuberin Regulates the DNA Repair Enzyme OGG1. American Journal of Physiology Renal Physiology. 2008, 294: F281-F290. 10.1152/ajprenal.00370.2007CrossRefPubMed

24.

Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi A: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst (Bethesda). 2000, 92: 1252-1259. 10.1093/jnci/92.15.1252. 10.1093/jnci/92.15.1252CrossRef

25.

Robb VA, Astrinidis A, Henske EP: Hyperphosphorylation of ribosomal protein S6 in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol. 2006, 19: 839-846. 10.1038/modpathol.3800624CrossRefPubMed

26.

Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS: The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem. 2003, 278: 5947-51. 10.1074/jbc.C200473200CrossRefPubMed

27.

Kenerson HL, Aicher LD, True LD, Yeung RS: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002, 62: 5645-50.PubMed

28.

Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS: Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol. 2005, 167: 107-16.PubMedCentralCrossRefPubMed

29.

Crino PB, Trojanowski JQ, Dichter MA, Eberwine J: Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. Proc Natl Acad Sci USA. 1996, 93: 14152-7. 10.1073/pnas.93.24.14152PubMedCentralCrossRefPubMed

30.

Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3CrossRefPubMed

Title: Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients
Author: Samy L Habib
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-8-13

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action

Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus Latent Membrane Protein-1

The rapamycin-regulated gene expression signature determines prognosis for breast cancer

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion

microRNA evaluation of unknown primary lesions in the head and neck

Keynote webinar | Spotlight on antibody–drug conjugates in cancer